ZIOPHARM Oncology

ZIOPHARM Oncology, Inc., is a biopharmaceutical company focused on the discovery and development of new cancer therapies. We are applying the latest technologies in cancer research to develop safer, more precise therapeutics to improve care and quality of life for patients.
Type
Public
HQ
Boston, US
Size (employees)
36 (est)+29%
ZIOPHARM Oncology is headquartered in Boston, US

Key People at ZIOPHARM Oncology

Jonathan Lewis

Jonathan Lewis

CEO
Caesar J. Belbel

Caesar J. Belbel

CLO

ZIOPHARM Oncology Office Locations

ZIOPHARM Oncology has an office in Boston

ZIOPHARM Oncology Metrics

ZIOPHARM Oncology Financial Metrics

Revenue (2016)

$6.9 m

Revenue growth (2015-16), %

58%

Net income (2016)

($165.3 m)

Market capitalization (28-Apr-2017)

$920.1 m

Closing share price (28-Apr-2017)

$7.5

Cash (31-Dec-2016)

$81.1 m
ZIOPHARM Oncology's current market capitalization is $920.1 m.
ZIOPHARM Oncology's revenue was reported to be $6.9 m in FY, 2016 which is a 58% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$800 k$1.4 m$4.3 m$6.9 m

Revenue growth, %

72%216%58%

Operating expense total

$359.2 m$44.9 m$124.4 m$172.2 m

EBIT

($356.9 m)($43.5 m)($120.1 m)($165.3 m)

EBIT margin, %

(44614%)(3168%)(2772%)(2409%)

Net Income

($340.8 m)($31.8 m)($120.1 m)($165.3 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$68.2 m$42.8 m$140.7 m$81.1 m

Accounts Receivable

Inventories

$1.9 m$1.1 m$11.4 m$23.8 m

Current Assets

$70.3 m$44.1 m$152.5 m$104.9 m

PP&E

$801 k$531 k$581 k$843 k

Total Assets

$71.8 m$45.2 m$153.7 m$106.3 m

Accounts Payable

$422 k$2 m$2 m$156 k

Current Liabilities

$7.8 m$10.8 m$18.1 m$15.8 m

Retained Earnings

($372.6 m)($492.7 m)($658 m)

Total Equity

$49.4 m$33.8 m$87.4 m($77.3 m)

Financial Leverage

1.5 x1.3 x1.8 x-1.4 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($57.1 m)($31.8 m)($120.1 m)($165.3 m)

Depreciation and Amortization

$738 k$462 k$357 k$290 k

Accounts Receivable

Inventories

$5 m$809 k($10 m)($12 m)

Accounts Payable

($1.1 m)$1.6 m$4 k($1.9 m)

Cash From Operating Activities

($59.5 m)($36.7 m)($10 k)($58.3 m)

Purchases of PP&E

($132 k)($193 k)($412 k)($551 k)

Cash From Investing Activities

($131 k)($193 k)($412 k)($551 k)

Cash From Financing Activities

$54.5 m$11.4 m$98.3 m($788 k)

Interest Paid

Income Taxes Paid

ZIOPHARM Oncology Market Value History

ZIOPHARM Oncology News

ZIOPHARM Oncology Company Life

You may also be interested in